NARA Discovery
Article Details
← Back to Search Results
Journal Article

A comparative biodistribution study of polymeric and lipid-based nanoparticles

Andreas K. O. Åslund; Rob J. Vandebriel; Fanny Caputo; Wim H. de Jong; Christiaan Delmaar; Astrid Hyldbakk; Emilie Rustique; Ruth Schmid; Sofie Snipstad; Isabelle Texier; Kai Vernstad; Sven Even F. Borgos
Drug Delivery and Translational Research · Vol. 12, Issue 9 · pp. 2114-2131 · 2022

Abstract

Biodistribution of nanoencapsulated bioactive compounds is primarily determined by the size, shape, chemical composition and surface properties of the encapsulating nanoparticle, and, thus, less dependent on the physicochemical properties of the active pharmaceutical ingredient encapsulated. In the current work, we aimed to investigate the impact of formulation type on biodistribution profile for two clinically relevant nanoformulations. We performed a comparative study of biodistribution in healthy rats at several dose levels and durations up to 14-day post-injection. The studied nanoformulations were nanostructured lipid carriers incorporating the fluorescent dye IR780-oleyl, and polymeric nanoparticles containing the anticancer agent cabazitaxel. The biodistribution was approximated by quantification of the cargo in blood and relevant organs. Several clear and systematic differences in biodistribution were observed, with the most pronounced being a much higher (more than 50-fold) measured concentration ratio between cabazitaxel in all organs vs. blood, as compared to IR780-oleyl. Normalized dose linearity largely showed opposite trends between the two compounds after injection. Cabazitaxel showed a higher brain accumulation than IR780-oleyl with increasing dose injected. Interestingly, cabazitaxel showed a notable and prolonged accumulation in lung tissue compared to other organs. The latter observations could warrant further studies towards a possible therapeutic indication within lung and conceivably brain cancer for nanoformulations of this highly antineoplastic compound, for which off-target toxicity is currently dose-limiting in the clinic. Graphical abstract

Bibliographic Information

JournalDrug Delivery and Translational Research
PublisherSpringer
Publication Date2022-09-01
Publication Year2022
Volume12
Issue9
Pages2114-2131
Document TypeJournal Article
Print ISSN2190-393X
eISSN2190-3948
DOI10.1007/s13346-022-01157-y

Access Information

NARA Access Coverage2011-01-01~Current
Journal Homepagehttps://www.springer.com/journal/13346
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.